Stryker Corporation (SYK)

Medical device maker Stryker Corporation (SYK) benefits from more procedures, sales, and acquisitions.

As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.

Wall Street analysts rerated Stryker Corp SYK Wednesday after the company's fourth-quarter print.

SYK announces agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC.

SYK's fourth-quarter results reflect strong segmental performance, along with a rise in operating margin.

Stryker Corporation (NYSE:SYK ) Q4 2024 Earnings Conference Call January 28, 2025 4:30 PM ET Company Participants Kevin Lobo - Chairman, CEO & President Andy Pierce - Group President of MedSurg & Neur...

Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stree...

Stryker (SYK) came out with quarterly earnings of $4.01 per share, beating the Zacks Consensus Estimate of $3.87 per share. This compares to earnings of $3.46 per share a year ago.

Stryker beat Wall Street estimates for fourth-quarter profit and forecast 2025 earnings largely above expectations on Tuesday, fueled by strong demand for its medical and surgical devices.

SYK's fourth-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Stryker Corporation is a high-quality, innovative medical device company with a strong history of revenue, earnings, and FCF growth, driven by R&D and M&A strategies. Shares are currently expensive wi...

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with th...

Beyond analysts' top -and-bottom-line estimates for Stryker (SYK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportu...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inari Medical, I...

SYK inks an agreement to acquire Inari Medical at a valuation of approximately $4.9 billion.

Inari Medical (NARI) stock skyrocketed Monday afternoon and again Tuesday morning after a report that it was close to being acquired by Stryker (SYK) proved to be true.

On Monday, Stryker Corporation SYK agreed to acquire Inari Medical Inc. NARI for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion.

Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion late Monday. Inari stock catapulted on the news.